Retinal Pigment Epithelium (RPE) Exosomes

Overview

Parent Cell: Akira Retinal Pigment Epithelium (RPE) Cells differentiated from UCT-WJ-MSCs | RPE growth factors and miRNAs for RPE repair and regeneration

Related: Exosomes Overview • Retinal Epithelium Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira RPE Exosome Matrix is derived from retinal pigment epithelium (RPE) cells produced by directed differentiation of UCT-WJ-MSCs through neuroectoderm and optic vesicle intermediate stages. RPE identity is confirmed by co-expression of RPE65 (retinoid cycle enzyme), BESTROPHIN1 (ion channel), CRALBP (retinaldehyde binding), and characteristic cobblestone morphology with pigmentation. RPE65 and CRALBP confirm functional visual cycle competency of the source cells.

The RPE monolayer is the primary support tissue for photoreceptors — providing nutrient transport, retinoid recycling, phagocytosis of shed photoreceptor outer segments, and barrier function at the outer blood-retinal barrier. RPE dysfunction and loss is the central event in age-related macular degeneration (AMD) and several inherited retinal dystrophies. This exosome preparation delivers RPE-specific paracrine signals — most notably PEDF (pigment epithelium-derived factor), the most potent photoreceptor survival factor known — in a concentrated, targeted matrix.^[1]

This is the only 2 mL format in the standard catalog (200B+), reflecting the specialized delivery requirements of subretinal and periocular administration research contexts.

Mechanism of Action

Photoreceptor Neuroprotection (PEDF & BDNF): PEDF (pigment epithelium-derived factor) is the dominant photoreceptor survival factor secreted by RPE cells, binding PEDF-R on rods and cones to activate PI3K/Akt survival signaling,^{[2] [3]} providing potent anti-apoptotic, anti-angiogenic, and neuroprotective signaling to rod and cone photoreceptors. BDNF provides additional TrkB-mediated photoreceptor survival support — both factors have demonstrated neuroprotection in a light-induced photoreceptor phototoxicity model, alongside bFGF.^[4] miR-204 — a signature RPE miRNA — regulates the RPE transcriptional program and photoreceptor support functions. Together these cargo components support photoreceptor survival in the context of RPE loss or dysfunction.^[5]

Retinal Neovascularization Control: Pathological choroidal neovascularization (CNV) in wet AMD is driven by RPE-derived VEGF dysregulation in the context of Bruch's membrane disruption — reflecting a broader equilibrium shift between angiogenic VEGF and anti-angiogenic PEDF signaling.^[6] RPE-derived exosomes deliver PEDF — which antagonizes VEGF-driven angiogenesis — alongside miR-126, an endothelial-specific miRNA governing vascular integrity and angiogenesis,^[7] and miR-21 that regulate the angiogenic balance in the subretinal space. This anti-angiogenic cargo is relevant to wet AMD, polypoidal choroidal vasculopathy, and other CNV conditions;^[8] gene-therapy approaches targeting the same VEGF axis (e.g. RGX-314) are in parallel clinical development for neovascular AMD.^[9]

Outer Blood-Retinal Barrier Restoration: ZO-1-associated cargo maintains tight junction integrity in the RPE monolayer, preserving the outer blood-retinal barrier that separates the photoreceptor layer from choroidal blood supply.^[10] Barrier disruption allows fluid accumulation (subretinal and intraretinal fluid) that damages photoreceptors. RPE exosomes deliver tight junction-associated signals that promote barrier restoration in damaged or degenerated RPE.

Retinoid Cycle Support: RPE65 and CRALBP-associated cargo participate in the visual cycle — the enzymatic conversion of all-trans retinal to 11-cis retinal required for photoreceptor resensitization following light exposure. Exosome delivery of RPE65-associated molecular signals is relevant to Leber congenital amaurosis (RPE65 mutations) and other retinoid cycle defects.

Key Molecular Cargo

Potential Applications

• Age-Related Macular Degeneration: PEDF photoreceptor survival; anti-VEGF CNV modulation; RPE barrier restoration.
• Retinitis Pigmentosa: CNTF and BDNF rod photoreceptor survival (CNTF evidence is mixed across species — intravitreal CNTF failed to prevent photoreceptor loss in a canine RPGR-mutant model despite causing peripheral remodeling^[11]); miR-146a neuroinflammation suppression (mechanism proposed, not RP-specific).
• Stargardt Disease: RPE support cargo; retinoid cycle-associated signaling relevant to ABCA4 mutation research.
• Leber Congenital Amaurosis: RPE65-associated cargo; retinoid cycle biology relevant to RPE65 gene therapy support research.
• Diabetic Macular Edema: Outer blood-retinal barrier restoration via ZO-1 cargo; anti-VEGF modulation.
• Choroidal Neovascularization: PEDF anti-angiogenic activity counterbalances VEGF-driven CNV.
• Retinal Vein Occlusion: Anti-inflammatory secretome; VEGF regulation; ischemic retina neuroprotection via BDNF.
• Geographic Atrophy: RPE survival and function support; outer retinal neuroprotection in late dry AMD — mechanistic rationale, no geographic-atrophy-specific exosome efficacy data yet.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The evidence base for this exosome preparation is preclinical and mechanistic rather than product-specific clinical trial data — it draws on the biology of its individual cargo molecules (PEDF, BDNF, CNTF, miR-126, miR-204) and on trial data from whole-cell RPE transplantation using the same source lineage.